Log in to search using one of your social media accounts:

 

Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies

We present three patients with high-risk gastrointestinal malignancies complicated by cancer-associated VTE with progression of thrombosis while treated with the oral direct Xa inhibitor rivaroxaban. Upon switching therapy to low molecular weight heparin, we found that these patients had clinical and radiologic improvement of VTE. More studies are needed to evaluate the efficacy of rivaroxaban in high-risk gastrointestinal-VTE. We suggest that in some patients, DOACs may not be sufficient for the treatment of VTEs related to high-risk gastrointestinal malignancies.
Source: Blood Coagulation and Fibrinolysis - Category: Hematology Tags: Case Reports Source Type: research

Related Links:

Semin Thromb Hemost DOI: 10.1055/s-0038-1642644Death is more frequent than nonfatal recurrent venous thromboembolism (VTE) and major bleeding after acute VTE. The analysis of the causes of death is fundamental to explore new strategies to reduce mortality rates in these patients. The authors performed a meta-analysis to analyze mortality and independently adjudicated causes of death in anticoagulated patients due to VTE, and to evaluate potential differences between different anticoagulant schemes. They searched MEDLINE and CENTRAL, from January 1, 2000, to January 31, 2017, and performed additional searches in Web sites o...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
Semin Thromb Hemost DOI: 10.1055/s-0038-1648229Cancer patients may experience nonvalvular atrial fibrillation (AF) as a manifestation of cardiotoxicity. AF may be a direct effect of a neoplasm or, more often, appear as a postsurgical complication, especially after thoracic surgery. AF may also develop as a consequence of anticancer therapy (chemotherapy or radiotherapy), a condition probably underestimated. Cancer patients with AF require a multidisciplinary approach involving oncologists/hematologists, cardiologists, and coagulation experts. An echocardiogram should be performed to detect possible abnormalities of left ve...
Source: Seminars in Thrombosis and Hemostasis - Category: Hematology Authors: Tags: Review Article Source Type: research
AbstractPatients with primary or metastatic brain tumors are at increased risk of developing venous thromboses. However, the potential benefit of therapeutic anticoagulation in these patients must be weighed against the deadly complication of intracranial hemorrhage. In this review, we summarize available evidence and recent studies of intracranial bleeding risks in primary and metastatic tumors and the impact of therapeutic anticoagulation. We find that for the majority of primary and treated metastatic brain tumors, the risk of spontaneous bleeding is acceptable and not further increased by careful therapeutic anticoagul...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Lung Cancer, Neuro-Oncology, Symptom Management and Supportive Care Source Type: research
Introduction: Treatment of cancer-associated venous thrombosis (CAT) is challenging due to patients ’ increased risk of recurrent venous thromboembolism (VTE) and bleeding. CAT treatment guidelines recommend oral anticoagulation (OAC) be reserved for patients unable or unwilling to use long-term parenteral therapy but do not differentiate between warfarin and direct-acting OACs.
Source: Thrombosis Research - Category: Hematology Authors: Source Type: research
Introduction: Cancer patients with acute venous thromboembolism (VTE) are at increased risk of recurrent thrombosis and anticoagulant-associated bleeding compared to non-cancer patients with VTE. Long-term low molecular weight heparin (LMWH) has hitherto been the standard treatment for cancer patients with VTE. Data comparing LMWH with direct oral anticoagulants in cancer patients with VTE were limited.
Source: Thrombosis Research - Category: Hematology Authors: Source Type: research
Introduction: Anticoagulant treatment in cancer patients with venous thromboembolism (VTE) is challenging due to cancer-associated hypercoagulability and increased bleeding risk. Low-molecular-weight-heparin (LMWH) is the recommended treatment but rivaroxaban could be an attractive alternative because the once daily, oral dosing obviates the need for subcutaneous injections combined with short half-life and lower price.
Source: Thrombosis Research - Category: Hematology Authors: Tags: PO-84 Source Type: research
Introduction: Non-vitamin K oral antagonists (NOACs) are used to prevent thromboembolic complications in patients with atrial fibrillation (AF) due to easy administration with no need for routine monitoring compared with vitamin K antagonists (VKA). Only few treatment options are available for patients receiving NOACs with life-threatening bleeding, and the management may be further complicated in cancer patients due to interactions with the hemostatic system.
Source: Thrombosis Research - Category: Hematology Authors: Tags: PO-46 Source Type: research
Introduction: Treatment of cancer-associated venous thrombosis (CAT) is challenging due to patients ’ increased risk of recurrent venous thromboembolism (VTE) and bleeding. CAT treatment guidelines recommend oral anticoagulation (OAC) be reserved for patients unable or unwilling to use long-term parenteral therapy but do not differentiate between warfarin and direct-acting OACs.
Source: Thrombosis Research - Category: Hematology Authors: Source Type: research
Introduction: Anticoagulant treatment in cancer patients with venous thromboembolism (VTE) is challenging due to cancer-associated hypercoagulability and increased bleeding risk. Low-molecular-weight-heparin (LMWH) is the recommended treatment but rivaroxaban could be an attractive alternative because the once daily, oral dosing obviates the need for subcutaneous injections combined with short half-life and lower price.
Source: Thrombosis Research - Category: Hematology Authors: Tags: PO-84 Source Type: research
Introduction: Cancer patients with acute venous thromboembolism (VTE) are at increased risk of recurrent thrombosis and anticoagulant-associated bleeding compared to non-cancer patients with VTE. Long-term low molecular weight heparin (LMWH) has hitherto been the standard treatment for cancer patients with VTE. Data comparing LMWH with direct oral anticoagulants in cancer patients with VTE were limited.
Source: Thrombosis Research - Category: Hematology Authors: Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Gastroenterology | Hematology | Oral Cancer | Study | Thrombosis